News

BIO Ventures for Global Health Launches New Online Tool

Global Health Primer by Disease

This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development. The Primer identifies gaps in the product pipeline for these diseases helping to highlight areas where companies and others can add effort and make the most progress. Content for the tool includes:

  • Creation of drug target and vaccine technology profiles in addition to the neglected disease profiles. These profiles group products in development by drug target classes and vaccine technologies that may span multiple diseases.
  • Expansion of each disease profile to include drug target and vaccine technology analysis that spotlights opportunities for application to neglected tropical diseases.
  • Greater analysis of strengths, weaknesses, opportunities, and risks for products currently in development for neglected tropical diseases, as well as information on development tools that are available to facilitate new product development

Click here to check out the Global Health Primer for TB

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...